Clinical Trials Directory

Trials / Conditions / Castration Levels of Testosterone

Castration Levels of Testosterone

19 registered clinical trials studyying Castration Levels of Testosterone — 1 currently recruiting.

StatusTrialSponsorPhase
WithdrawnEnzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer
NCT03709550
Roswell Park Cancer InstitutePhase 1 / Phase 2
CompletedApalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer
NCT03503344
University of California, San FranciscoPhase 2
TerminatedESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
NCT04159896
Barbara Ann Karmanos Cancer InstitutePhase 2
UnknownsEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04033432
Northwestern UniversityPhase 2
CompletedEnzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer
NCT03751436
Roswell Park Cancer InstitutePhase 1
Completed177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
NCT03805594
University of California, San FranciscoPhase 1
RecruitingStandard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prosta
NCT03678025
SWOG Cancer Research NetworkPhase 3
TerminatedDocetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Pros
NCT03442556
University of WashingtonPhase 2
CompletedPembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate C
NCT03406858
Barbara Ann Karmanos Cancer InstitutePhase 2
WithdrawnDurvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT02966587
University of WashingtonPhase 2
Active Not RecruitingAbiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients W
NCT03419234
ECOG-ACRIN Cancer Research GroupPhase 2
CompletedESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer
NCT03456804
Barbara Ann Karmanos Cancer InstitutePhase 2
Active Not RecruitingAbiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in
NCT02703623
M.D. Anderson Cancer CenterPhase 2
CompletedDocetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containin
NCT02598895
University of WashingtonPhase 2
CompletedNiclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer
NCT02532114
University of WashingtonPhase 1
TerminatedSelinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-R
NCT02215161
University of California, San FranciscoPhase 2
CompletedCYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT01881867
Fred Hutchinson Cancer CenterPhase 2
CompletedMolecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant
NCT02228265
OHSU Knight Cancer Institute—
CompletedCabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Res
NCT01505868
M.D. Anderson Cancer CenterPhase 1 / Phase 2